Lorena Madrid-Farinas

Bellaterra, CT 08193, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA Status.

Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA Status.

Journal: Cancers

Published: May 06, 2026

The game changer in the cervical cancer therapeutic landscape: immunotherapy.

The game changer in the cervical cancer therapeutic landscape: immunotherapy.

Journal: Immunotherapy

Published: April 10, 2026

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

Journal: ESMO open

Published: September 01, 2025

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 31, 2025

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

Journal: Gynecologic oncology

Published: May 13, 2024

Immunotherapy in the treatment of advanced or recurrent endometrial cancer.

Immunotherapy in the treatment of advanced or recurrent endometrial cancer.

Journal: Clinical advances in hematology & oncology : H&O

Published: April 08, 2024

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 25, 2024

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: September 26, 2023

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 05, 2023

Advances in immunotherapy in cervical cancer.

Advances in immunotherapy in cervical cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 06, 2023

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

Journal: Cancers

Published: December 21, 2021

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.

Journal: Scientific reports

Published: October 01, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026